ClinVar Miner

Submissions for variant NM_147127.5(EVC2):c.3265C>T (p.Gln1089Ter)

gnomAD frequency: 0.00008  dbSNP: rs137852927
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000799858 SCV000939540 pathogenic Ellis-van Creveld syndrome; Curry-Hall syndrome 2024-09-16 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln1089*) in the EVC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EVC2 are known to be pathogenic (PMID: 17024374, 19810119, 19876929). This variant is present in population databases (rs137852927, gnomAD 0.2%). This premature translational stop signal has been observed in individual(s) with autosomal recessive Ellis-van Creveld syndrome (PMID: 12468274, 23220543). This variant is also known as C3754T (Q1009X). ClinVar contains an entry for this variant (Variation ID: 3386). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000003553 SCV000967782 pathogenic Ellis-van Creveld syndrome 2018-10-10 criteria provided, single submitter clinical testing The p.Gln1089X variant in EVC2 has been reported in the homozygous state in one individual with Ellis-van Creveld syndrome (Galdzicka 2002). It has also been id entified in 0.15% (15/9850) of European chromosomes by gnomAD (http://gnomad.bro adinstitute.org). This nonsense variant leads to a premature termination codon a t position 1089, which is predicted to lead to a truncated or absent protein. Bi allelic loss of function variants in EVC2 have been reported as disease causing in several individuals with Ellis-van Creveld syndrome. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Ellis-van Creveld syndrome based on a case observation and the predicted impact on the pr otein. ACMG/AMP criteria applied: PVS1, PP4, PM3_Supporting.
Myriad Genetics, Inc. RCV000003553 SCV001193772 pathogenic Ellis-van Creveld syndrome 2019-12-20 criteria provided, single submitter clinical testing NM_147127.4(EVC2):c.3265C>T(Q1089*) is classified as pathogenic in the context of EVC2-related Ellis-van Creveld syndrome. Sources cited for classification include the following: PMID 23220543 and 12468274. Classification of NM_147127.4(EVC2):c.3265C>T(Q1089*) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening.
Ambry Genetics RCV001265673 SCV001443840 pathogenic Inborn genetic diseases 2017-12-18 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV000799858 SCV002813111 pathogenic Ellis-van Creveld syndrome; Curry-Hall syndrome 2024-03-25 criteria provided, single submitter clinical testing
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV000003553 SCV005399114 pathogenic Ellis-van Creveld syndrome 2022-03-31 criteria provided, single submitter clinical testing Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Loss of function is a known mechanisms of disease in this gene and are associated with recessive Ellis-van Creveld syndrome (MIM#225500). Gain of function and dominant negative is likely the mechanism associated with dominant Weyers acrofacial dysostosis (MIM#193530) (PMID: 19810119). (I) 0108 - This gene is associated with both recessive and dominant disease (OMIM). (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (20 heterozygotes, 0 homozygotes). (SP) 0701 - Other NMD predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (ClinVar). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported in both homozygous and compound heterozgyous individuals with Ellis-van Creveld syndrome (PMID: 12468274, 23220543). It has also been reported multiple times as pathogenic in ClinVar. (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
GeneDx RCV005054132 SCV005687919 pathogenic not provided 2024-07-31 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 19876929, 25525159, 23220543, 12468274, 31980526, 34682862, 38163170, 30476936, 31428121)
OMIM RCV000003553 SCV000023711 pathogenic Ellis-van Creveld syndrome 2002-12-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.